Tumour predisposition and cancer syndromes as models to study gene-environment interactions.
Journal
Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
accepted:
23
04
2020
pubmed:
31
5
2020
medline:
20
11
2020
entrez:
31
5
2020
Statut:
ppublish
Résumé
Cell division and organismal development are exquisitely orchestrated and regulated processes. The dysregulation of the molecular mechanisms underlying these processes may cause cancer, a consequence of cell-intrinsic and/or cell-extrinsic events. Cellular DNA can be damaged by spontaneous hydrolysis, reactive oxygen species, aberrant cellular metabolism or other perturbations that cause DNA damage. Moreover, several environmental factors may damage the DNA, alter cellular metabolism or affect the ability of cells to interact with their microenvironment. While some environmental factors are well established as carcinogens, there remains a large knowledge gap of others owing to the difficulty in identifying them because of the typically long interval between carcinogen exposure and cancer diagnosis. DNA damage increases in cells harbouring mutations that impair their ability to correctly repair the DNA. Tumour predisposition syndromes in which cancers arise at an accelerated rate and in different organs - the equivalent of a sensitized background - provide a unique opportunity to examine how gene-environment interactions influence cancer risk when the initiating genetic defect responsible for malignancy is known. Understanding the molecular processes that are altered by specific germline mutations, environmental exposures and related mechanisms that promote cancer will allow the design of novel and effective preventive and therapeutic strategies.
Identifiants
pubmed: 32472073
doi: 10.1038/s41568-020-0265-y
pii: 10.1038/s41568-020-0265-y
pmc: PMC8104546
mid: NIHMS1595145
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-549Subventions
Organisme : NCI NIH HHS
ID : R01 CA198138
Pays : United States
Organisme : NIGMS NIH HHS
ID : R37 GM026017
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA077852
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197706
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA237235
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM026017
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA111295
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA214195
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES030948
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM050006
Pays : United States
Références
Tomasetti, C. & Vogelstein, B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78–81 (2015).
pubmed: 25554788
pmcid: 4446723
Tomasetti, C., Li, L. & Vogelstein, B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 355, 1330–1334 (2017).
pubmed: 28336671
pmcid: 5852673
Wu, S., Powers, S., Zhu, W. & Hannun, Y. A. Substantial contribution of extrinsic risk factors to cancer development. Nature 529, 43–47 (2016).
pubmed: 26675728
Wu, S., Zhu, W., Thompson, P. & Hannun, Y. A. Evaluating intrinsic and non-intrinsic cancer risk factors. Nat. Commun. 9, 3490 (2018).
pubmed: 30154431
pmcid: 6113228
Carbone, M., Klein, G., Gruber, J. & Wong, M. Modern criteria to establish human cancer etiology. Cancer Res. 64, 5518–5524 (2004).
pubmed: 15289363
Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880–886 (2015).
pubmed: 25999502
pmcid: 25999502
Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018).
pubmed: 30337457
pmcid: 30337457
Huang, K. L. et al. Pathogenic germline variants in 10,389 adult cancers. Cell 173, 355–370 e314 (2018).
pubmed: 29625052
pmcid: 5949147
Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302–308 (2014).
pubmed: 24429628
pmcid: 4975511
McGee, R. B. & Nichols, K. E. Introduction to cancer genetic susceptibility syndromes. Hematol. Am. Soc. Hematol Educ. Program 2016, 293–301 (2016).
Sondka, Z. et al. The COSMIC cancer gene census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696–705 (2018).
pubmed: 30293088
pmcid: 6450507
Carbone, M. et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat. Rev. Cancer 7, 147–154 (2007).
pubmed: 17251920
Emri, S. A. The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad. Ann. Transl Med. 5, 239 (2017).
pubmed: 28706907
pmcid: 5497117
Baumann, F., Ambrosi, J. P. & Carbone, M. Asbestos is not just asbestos: an unrecognised health hazard. Lancet. Oncol. 14, 576–578 (2013).
pubmed: 23725699
Alpert, N., Gerwen, Mv. & Taioli, E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. https://doi.org/10.21037/tlcr.2019.11.11 (2019).
doi: 10.21037/tlcr.2019.11.11
Carbone, M. et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J. Clin. 69, 402–429 (2019).
pubmed: 31283845
Sluis-Cremer, G. K., Liddell, F. D., Logan, W. P. & Bezuidenhout, B. N. The mortality of amphibole miners in South Africa, 1946–80. Br. J. Ind. Med. 49, 566–575 (1992).
pubmed: 1325180
pmcid: 1039290
Carbone, M. et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc. Natl Acad. Sci. USA 108, 13618–13623 (2011).
pubmed: 21788493
Roushdy-Hammady, I., Siegel, J., Emri, S., Testa, J. R. & Carbone, M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357, 444–445 (2001).
pubmed: 11273069
Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153–159 (2013).
pubmed: 23550303
pmcid: 3792854
Carbone, M. et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl Med. 10, 179 (2012).
pubmed: 22935333
pmcid: 3493315
Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022–1025 (2011).
pubmed: 21874000
pmcid: 3184199
Abdel-Rahman, M. H. et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856–859 (2011).
pubmed: 21941004
Yu, M. D., Masoomian, B., Shields, J. A. & Shields, C. L. BAP1 germline mutation associated with bilateral primary uveal melanoma. Ocular Oncol. Pathol. 6, 10–14 (2020).
Farley, M. N. et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol. Cancer Res. 11, 1061–1071 (2013).
pubmed: 23709298
pmcid: 4211292
Carbone, M. et al. Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s. PLoS Genet. 11, e1005633 (2015).
pubmed: 26683624
pmcid: 4686043
Yoshikawa, Y., Emi, M., Nakano, T. & Gaudino, G. Mesothelioma developing in carriers of inherited genetic mutations. Transl Lung Cancer Res. 9 (Suppl. 1), S67–S76 (2019).
Haugh, A. M. et al. Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature. JAMA Dermatol. 153, 999–1006 (2017).
pubmed: 28793149
pmcid: 5710339
Walpole, S. et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J. Natl Cancer Inst. 110, 1328–1341 (2018).
pubmed: 30517737
pmcid: 6292796
Bononi, A. et al. BAP1 regulates IP3R3-mediated Ca
pubmed: 28614305
pmcid: 5581194
Napolitano, A. et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35, 1996–2002 (2016).
pubmed: 26119930
Kadariya, Y. et al. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 76, 2836–2844 (2016).
pubmed: 26896281
pmcid: 4873414
Hickson, I. D. RecQ helicases: caretakers of the genome. Nat. Rev. Cancer 3, 169–178 (2003).
pubmed: 12612652
Oshima, J., Sidorova, J. M. & Jr. Monnat, R. J. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. Ageing Res. Rev. 33, 105–114 (2017).
pubmed: 26993153
Killen, M. W., Stults, D. M., Adachi, N., Hanakahi, L. & Pierce, A. J. Loss of Bloom syndrome protein destabilizes human gene cluster architecture. Hum. Mol. Genet. 18, 3417–3428 (2009).
pubmed: 19542097
Moser, M. J. et al. Genetic instability and hematologic disease risk in Werner syndrome patients and heterozygotes. Cancer Res. 60, 2492–2496 (2000).
pubmed: 10811130
Boveri, T. Zur Frage der Entstehung maligner Tumoren (Gustav Ficher, 1914).
Lauper, J. M., Krause, A., Vaughan, T. L. & Jr. Monnat, R. J. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One 8, e59709 (2013).
pubmed: 23573208
pmcid: 3613408
German, J. Bloom’s syndrome. XX. The first 100 cancers. Cancer Genet. Cytogenet. 93, 100–106 (1997).
pubmed: 9062585
Gruber, S. B. et al. BLM heterozygosity and the risk of colorectal cancer. Science 297, 2013 (2002).
pubmed: 12242432
Goss, K. H. et al. Enhanced tumor formation in mice heterozygous for Blm mutation. Science 297, 2051–2053 (2002).
pubmed: 12242442
Yao, Y. & Dai, W. Genomic instability and cancer. J. Carcinog. Mutagen. 5, 1000163 (2014).
Yang, H. et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis. 6, e1786 (2015).
pubmed: 26068794
pmcid: 4669834
Gaudino, G., Xue, J. & Yang, H. How asbestos and other fibers cause mesothelioma. Translational Lung Cancer Res. 9 (Suppl. 1), S39–S46 (2020).
Kolodner, R. D. A personal historical view of DNA mismatch repair with an emphasis on eukaryotic DNA mismatch repair. DNA Repair. 38, 3–13 (2016).
pubmed: 26698650
Graham, V. W. J., Putnam, C. D. & Kolodner, R. D. DNA mismatch repair: mechanisms and cancer genetics. Encycl. Cancer 1, 530–538 (2019).
Giorgi, C. et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 330, 1247–1251 (2010).
pubmed: 21030605
pmcid: 3017677
Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 (2004).
pubmed: 15516961
Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85–95 (2011).
pubmed: 21258394
Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170, 1062–1078 (2017).
pubmed: 28886379
pmcid: 5743327
Yu, H. et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc. Natl Acad. Sci. USA 111, 285–290 (2014).
pubmed: 24347639
Giorgi, C., Bonora, M. & Pinton, P. Inside the tumor: p53 modulates calcium homeostasis. Cell Cycle 14, 933–934 (2015).
pubmed: 25715001
pmcid: 4613355
Zhang, Y. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol. 20, 1181–1192 (2018).
pubmed: 30202049
pmcid: 6170713
Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650–1653 (2006).
pubmed: 16728594
Wang, P. Y. et al. Increased oxidative metabolism in the Li-Fraumeni syndrome. N. Engl. J. Med. 368, 1027–1032 (2013).
pubmed: 23484829
pmcid: 4123210
Bononi, A. et al. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ. 24, 1694–1704 (2017).
pubmed: 28665402
pmcid: 5596430
Bougeard, G. et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J. Clin. Oncol. 33, 2345–2352 (2015).
pubmed: 26014290
Villani, A. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 17, 1295–1305 (2016).
pubmed: 27501770
Mai, P. L. et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122, 3673–3681 (2016).
pubmed: 27496084
pmcid: 5115949
Boettcher, S. et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science 365, 599–604 (2019).
pubmed: 31395785
pmcid: 7327437
Giacomelli, A. O. et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat. Genet. 50, 1381–1387 (2018).
pubmed: 30224644
pmcid: 6168352
Gonzalez, K. D. et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J. Med. Genet. 46, 689–693 (2009).
pubmed: 19556618
Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410–1413 (2010).
pubmed: 21051595
pmcid: 3087380
Yoshikawa, Y. et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc. Natl Acad. Sci. USA 113, 13432–13437 (2016).
pubmed: 27834213
Nasu, M. et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol. 10, 565–576 (2015).
pubmed: 25658628
pmcid: 4408084
Jin, S. et al. Comprehensive analysis of BAP1 somatic mutation in clear cell renal cell carcinoma to explore potential mechanisms in Silico. J. Cancer 9, 4108–4116 (2018).
pubmed: 30519310
pmcid: 6277624
Pena-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751–759 (2012).
pubmed: 22683710
pmcid: 3788680
Malkin, D. Li-fraumeni syndrome. Genes Cancer 2, 475–484 (2011).
pubmed: 21779515
pmcid: 3135649
Mashtalir, N. et al. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol. Cell 54, 392–406 (2014).
Bhattacharya, S., Hanpude, P. & Maiti, T. K. Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: a new insight in enzymatic inactivation. Sci. Rep. 5, 18462 (2015).
pubmed: 26680512
pmcid: 4683529
Heymann, S. et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat. Oncol. 5, 104 (2010).
pubmed: 21059199
pmcid: 2988810
Ziegler, A. et al. Sunburn and p53 in the onset of skin cancer. Nature 372, 773–776 (1994).
pubmed: 7997263
Marsella, J. M., Liu, B. L., Vaslet, C. A. & Kane, A. B. Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Env. Health Perspect. 105 (Suppl. 5), 1069–1072 (1997).
De Flora, S. et al. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke. Cancer Res. 63, 793–800 (2003).
pubmed: 12591728
Boyle, J. M. et al. Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families. Br. J. Cancer 77, 2181–2192 (1998).
pubmed: 9649131
pmcid: 2150396
Hajkova, N. et al. Germline mutation in the TP53 gene in uveal melanoma. Sci. Rep. 8, 7618 (2018).
pubmed: 29769598
pmcid: 5955881
Jiang, W., Ananthaswamy, H. N., Muller, H. K. & Kripke, M. L. p53 protects against skin cancer induction by UV-B radiation. Oncogene 18, 4247–4253 (1999).
pubmed: 10435637
Ford, J. M. & Hanawalt, P. C. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc. Natl Acad. Sci. USA 92, 8876–8880 (1995).
pubmed: 7568035
Kemp, C. J., Wheldon, T. & Balmain, A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 8, 66–69 (1994).
pubmed: 7987394
Nutting, C. et al. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin. Oncol. 12, 300–304 (2000).
Hwang, S. J. et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum. Genet. 113, 238–243 (2003).
pubmed: 12802680
Zhang, Z. et al. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents Taxol or Adriamycin. Cancer Res. 60, 901–907 (2000).
pubmed: 10706103
Krais, A. M. et al. The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53
pubmed: 25995008
Tsutsui, T. et al. Aflatoxin B1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome. Carcinogenesis 16, 25–34 (1995).
pubmed: 7834802
Cleaver, J. E., Lam, E. T. & Revet, I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat. Rev. Gen. 10, 756–768 (2009).
Cleaver, J. E. & Revet, I. Clinical implications of the basic defects in Cockayne syndrome and xeroderma pigmentosum and the DNA lesions responsible for cancer, neurodegeneration and aging. Mech. Ageing Dev. 129, 492–497 (2008).
pubmed: 18336867
pmcid: 2517418
DiGiovanna, J. J. & Kraemer, K. H. Shining a light on xeroderma pigmentosum. J. Invest. Dermatol. 132, 785–796 (2012).
pubmed: 22217736
pmcid: 3279615
Zheng, C. L. et al. Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. Cell Rep. 9, 1228–1234 (2014).
pubmed: 25456125
pmcid: 4254608
Zhang, W. R., Garrett, G. L., Arron, S. T. & Cleaver, J. E. Survey of Cockayne patients reports no skin cancers despite DNA repair deficiency. J. Amer Acad. Dermatol. 74, 1270–1272 (2016).
Reid-Bayless, K. S., Arron, S. T., Loeb, L. A., Bezrookove, V. & Cleaver, J. E. Why Cockayne syndrome patients do not get cancer despite their DNA repair deficiency. Proc. Natl Acad. Sci. USA 113, 10151–101516 (2016).
Fujiwara, Y., Ichihashi, M., Kano, Y., Goto, K. & Shimuzu, K. A new human photosensitive subject with a defect in the recovery of DNA synthesis after ultraviolet-light irradiation. J. Investig. Dermatol. 77, 256–263 (1981).
pubmed: 7264357
Spivak, G. & Hanawalt, P. C. Host cell reactivation of plasmids containing oxidative DNA lesions is defective in Cockayne syndrome but normal in UV-sensitive syndrome fibroblasts. DNA Repair. 5, 13–22 (2006).
pubmed: 16129663
Cleaver, J. E. et al. Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage. Proc. Natl Acad. Sci. USA 111, 13487–13492 (2014).
pubmed: 25136123
Crossley, M. P., Bocek, M. & Cimprich, K. A. R-loops as cellular regulators and genomic threats. Mol. Cell 73, 398–411 (2019).
pubmed: 6402819
pmcid: 6402819
Cleaver, J. E. Transcription coupled repair deficiency protects against human mutagenesis and carcinogenesis: personal reflections on the 50th anniversary of the discovery of xeroderma pigmentosum. DNA Repair. 58, 21–28 (2017).
pubmed: 28846868
Cleaver, J. E. Normal reconstruction of DNA supercoiling and chromatin structure in Cockayne syndrome cells during repair of damage from ultraviolet light. Am. J. Hum. Genet. 34, 566–575 (1982).
pubmed: 7102674
pmcid: 1685362
Tresini, M. et al. The core spliceosome as target and effector of non-canonical ATM signalling. Nature 523, 53–58 (2015).
pubmed: 4501432
pmcid: 4501432
Parris, C. H. & Kraemer, K. H. Ultraviolet-light induced mutations in Cockayne syndrome cells are primarily caused by cyclobutane dimer photoproducts while repair of other photoproducts is normal. Proc. Natl Acad. Sci. USA 90, 7260–7264 (1993).
pubmed: 8346243
Berg, R. J. et al. Impact of global genome repair versus transcription-coupled repair on ultraviolet carcinogenesis in hairless mice. Cancer Res. 60, 2858–2863 (2000).
pubmed: 10850428
van Zeeland, A. A. et al. Transcription-coupled repair: impact on UV-induced mutagenesis in cultured rodent cells and mouse skin tumors. Mutat. Res. 577, 170–178 (2005).
pubmed: 15949822
Lynch, H. T., Snyder, C. L., Shaw, T. G., Heinen, C. D. & Hitchins, M. P. Milestones of Lynch syndrome: 1895–2015. Nat. Rev. Cancer 15, 181–194 (2015).
pubmed: 25673086
Jiricny, J. & Nystrom-Lahti, M. Mismatch repair defects in cancer. Curr. Opin. Genet. Dev. 10, 157–161 (2000).
pubmed: 10753784
Marsischky, G. T., Filosi, N., Kane, M. F. & Kolodner, R. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev. 10, 407–420 (1996).
pubmed: 8600025
Srivatsan, A., Bowen, N. & Kolodner, R. D. Mispair-specific recruitment of the Mlh1-Pms1 complex identifies repair substrates of the Saccharomyces cerevisiae Msh2-Msh3 complex. J. Biol. Chem. 289, 9352–9364 (2014).
pubmed: 24550389
pmcid: 3979400
Amin, N. S., Nguyen, M. N., Oh, S. & Kolodner, R. D. exo1-Dependent mutator mutations: model system for studying functional interactions in mismatch repair. Mol. Cell Biol. 21, 5142–5155 (2001).
pubmed: 11438669
pmcid: 87239
Boland, P. M., Yurgelun, M. B. & Boland, C. R. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J. Clin. 68, 217–231 (2018).
pubmed: 29485237
pmcid: 5980692
Lynch, H. T. & de la Chapelle, A. Genetic susceptibility to non-polyposis colorectal cancer. J. Med. Genet. 36, 801–818 (1999).
pubmed: 10544223
pmcid: 1734258
Wei, W. et al. Racial differences in MLH1 and MSH2 mutation: an analysis of yellow race and white race based on the InSiGHT database. J. Bioinform Comput. Biol. 8 (Suppl. 1), 111–125 (2010).
pubmed: 21155023
Park, H. M. et al. Colorectal cancer incidence in 5 Asian countries by subsite: an analysis of cancer incidence in five continents (1998–2007). Cancer Epidemiol. 45, 65–70 (2016).
pubmed: 27716537
Diergaarde, B. et al. Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin. Gastroenterol. Hepatol. 5, 736–742 (2007).
pubmed: 17544999
Gingras, D. & Beliveau, R. Colorectal cancer prevention through dietary and lifestyle modifications. Cancer Microenviron. 4, 133–139 (2011).
pubmed: 21909875
pmcid: 3170421
Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081–2087 (2011).
pubmed: 22036019
pmcid: 3243929
Burn, J., Mathers, J. C. & Bishop, D. T. Chemoprevention in Lynch syndrome. Fam. Cancer 12, 707–718 (2013).
pubmed: 23880960
Niraj, J., Farkkila, A. & D’Andrea, A. D. The Fanconi anemia pathway in cancer. Annu. Rev. Cancer Biol. 3, 457–478 (2019).
pubmed: 30882047
Rodriguez, A. & D’Andrea, A. Fanconi anemia pathway. Curr. Biol. 27, R986–R988 (2017).
pubmed: 28950089
Garaycoechea, J. I. et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 489, 571–575 (2012).
pubmed: 22922648
Langevin, F., Crossan, G. P., Rosado, I. V., Arends, M. J. & Patel, K. J. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 475, 53–58 (2011).
pubmed: 21734703
Kutler, D. I. et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Natl Cancer Inst. 95, 1718–1721 (2003).
pubmed: 14625263
van Zeeburg, H. J., Snijders, P. J., Joenje, H. & Brakenhoff, R. H. Re: human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Natl Cancer Inst. 96, 968 (2004).
pubmed: 15199119
Hira, A. et al. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood 122, 3206–3209 (2013).
pubmed: 24037726
pmcid: 3953058
Tyburczy, M. E. et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum. Mol. Genet. 23, 2023–2029 (2014).
pubmed: 24271014
Henske, E. P., Jozwiak, S., Kingswood, J. C., Sampson, J. R. & Thiele, E. A. Tuberous sclerosis complex. Nat. Rev. Dis. Prim. 2, 16035 (2016).
pubmed: 27226234
Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).
pubmed: 28283069
pmcid: 28283069
Yeung, R. S. et al. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc. Natl Acad. Sci. USA 91, 11413–11416 (1994).
pubmed: 7972075
Cook, J. D. et al. Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. Proc. Natl Acad. Sci. USA 102, 8644–8649 (2005).
pubmed: 15937110
Nickerson, M. L. et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2, 157–164 (2002).
pubmed: 12204536
Schmidt, L. S. & Linehan, W. M. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Nat. Rev. Urol. 12, 558–569 (2015).
pubmed: 26334087
pmcid: 5119524
de Kock, L., Wu, M. K. & Foulkes, W. D. Ten years of DICER1 mutations: provenance, distribution, and associated phenotypes. Hum. Mutat. 40, 1939–1953 (2019).
pubmed: 31342592
Miniati, D. N. et al. Prenatal presentation and outcome of children with pleuropulmonary blastoma. J. Pediatr. Surg. 41, 66–71 (2006).
pubmed: 16410110
Kurzynska-Kokorniak, A. et al. The many faces of Dicer: the complexity of the mechanisms regulating Dicer gene expression and enzyme activities. Nucleic Acids Res. 43, 4365–4380 (2015).
pubmed: 25883138
pmcid: 4482082
Gross, T. J. et al. A microRNA processing defect in smokers’ macrophages is linked to SUMOylation of the endonuclease DICER. J. Biol. Chem. 289, 12823–12834 (2014).
pubmed: 24668803
pmcid: 4007470
Taeubner, J. et al. Penetrance and expressivity in inherited cancer predisposing syndromes. Trends Cancer 4, 718–728 (2018).
pubmed: 30352675
Petljak, M. & Alexandrov, L. B. Understanding mutagenesis through delineation of mutational signatures in human cancer. Carcinogenesis 37, 531–540 (2016).
pubmed: 27207657
Nones, K. et al. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Ann. Oncol. 30, 1071–1079 (2019).
pubmed: 31090900
pmcid: 6637375
Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017).
pubmed: 28288110
pmcid: 5833945
Castellsague, E. et al. Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. Hum. Mutat. 40, 36–41 (2019).
pubmed: 30362666
Polak, P. et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat. Genet. 49, 1476–1486 (2017).
pubmed: 28825726
pmcid: 7376751
Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836 (2019).
pubmed: 30982602
pmcid: 6506336
Alexandrov, L. B. et al. Mutational signatures associated with tobacco smoking in human cancer. Science 354, 618–622 (2016).
pubmed: 27811275
pmcid: 6141049
Wild, C. P., Scalbert, A. & Herceg, Z. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Env. Mol. Mutagen. 54, 480–499 (2013).
Nik-Zainal, S. et al. The genome as a record of environmental exposure. Mutagenesis 30, 763–770 (2015).
pubmed: 26443852
pmcid: 4637815
Herceg, Z. et al. Roadmap for investigating epigenome deregulation and environmental origins of cancer. Int. J. Cancer 142, 874–882 (2018).
pubmed: 28836271
Siddeek, B., Mauduit, C., Simeoni, U. & Benahmed, M. Sperm epigenome as a marker of environmental exposure and lifestyle, at the origin of diseases inheritance. Mutat. Res. 778, 38–44 (2018).
pubmed: 30454681
Johansson, A. et al. Epigenome-wide association study for lifetime estrogen exposure identifies an epigenetic signature associated with breast cancer risk. Clin. Epigenetics 11, 66 (2019).
pubmed: 31039828
pmcid: 6492393
Martin, E. M. & Fry, R. C. Environmental Influences on the epigenome: exposure- associated DNA methylation in human populations. Annu. Rev. Public. Health 39, 309–333 (2018).
pubmed: 29328878
Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).
pubmed: 27135926
pmcid: 4910866
Degasperi, A. et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat. Cancer 1, 249–263 (2020).
pubmed: 32118208
pmcid: 7048622
Turnbull, C. et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ 361, k1687 (2018).
pubmed: 29691228
Elliott, P., Peakman, T. C. & Biobank, U. K. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37, 234–244 (2008).
pubmed: 18381398
Manolio, T. A. et al. New models for large prospective studies: is there a better way? Am. J. Epidemiol. 175, 859–866 (2012).
pubmed: 22411865
pmcid: 3339313
Sullivan, F., McKinstry, B. & Vasishta, S. The “All of Us” research program. N. Engl. J. Med. 381, 1883–1884 (2019).
pubmed: 31693824
Mouse Genome Sequencing Consortium. et al. Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520–562 (2002).
Moresco, E. M., Li, X. & Beutler, B. Going forward with genetics: recent technological advances and forward genetics in mice. Am. J. Pathol. 182, 1462–1473 (2013).
pubmed: 23608223
pmcid: 3644711
Arnold, C. N. et al. ENU-induced phenovariance in mice: inferences from 587 mutations. BMC Res. Notes 5, 577 (2012).
pubmed: 23095377
pmcid: 3532239
Wang, T. et al. Real-time resolution of point mutations that cause phenovariance in mice. Proc. Natl Acad. Sci. USA 112, E440–E449 (2015).
pubmed: 25605905
Mager, L. F. et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J. Clin. Invest. 125, 2579–2591 (2015).
pubmed: 26011644
pmcid: 4563674
de Vos tot Nederveen Cappel, W. H. et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis. Colon. Rectum 45, 1588–1594 (2002).
pubmed: 12473880
Jarvinen, H. J. et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118, 829–834 (2000).
pubmed: 10784581
Schmeler, K. M. et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 354, 261–269 (2006).
pubmed: 16421367
Lynch, H. T., Snyder, C. L., Lynch, J. F., Riley, B. D. & Rubinstein, W. S. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J. Clin. Oncol. 21, 740–753 (2003).
pubmed: 12586815
Kratz, C. P. et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin. Cancer Res. 23, e38–e45 (2017).
pubmed: 28572266
Vogel, W. H. Li-Fraumeni syndrome. J. Adv. Pract. Oncol. 8, 742–746 (2017).
pubmed: 30333936
pmcid: 6188099
Pastorino, S. et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J. Clin. Oncol. 36, 3485–3494 (2018).
pmcid: 7162737
Baumann, F. et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36, 76–81 (2015).
pubmed: 25380601
Kobrinski, D. A., Yang, H. & Kittaneh, M. BAP1: role in carcinogenesis and clinical implications. Transl Lung Cancer Res. 9 (Suppl. 1), S60–S66 (2019).
Wang, P. Y. et al. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J. Clin. Invest. 127, 132–136 (2017).
pubmed: 27869650
Achatz, M. I., Hainaut, P. & Ashton-Prolla, P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol. 10, 920–925 (2009).
pubmed: 19717094
Achatz, M. I. & Zambetti, G. P. The inherited p53 mutation in the Brazilian population. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a026195 (2016).
doi: 10.1101/cshperspect.a026195
pubmed: 27663983
pmcid: 5131754
DiGiammarino, E. L. et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat. Struct. Biol. 9, 12–16 (2002).
pubmed: 11753428
Park, J. H. et al. Mouse homolog of the human TP53 R337H mutation reveals its role in tumorigenesis. Cancer Res. 78, 5375–5383 (2018).
pubmed: 30042151
pmcid: 6139041
Macedo, G. S. et al. Increased oxidative damage in carriers of the germline TP53 p.R337H mutation. PLoS One 7, e47010 (2012).
pubmed: 23056559
pmcid: 3467233
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A. & D’Andrea, A. D. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 7, 675–693 (2017).
pubmed: 28630051
pmcid: 5659200
Reuter, S., Gupta, S. C., Chaturvedi, M. M. & Aggarwal, B. B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 49, 1603–1616 (2010).
pubmed: 20840865
pmcid: 2990475
Craven, P. A. & DeRubertis, F. R. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 13, 541–546 (1992).
pubmed: 1315625
Sheng, H. et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99, 2254–2259 (1997).
pubmed: 9151799
pmcid: 508057
Barnes, C. J. & Lee, M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114, 873–877 (1998).
pubmed: 9558273
Beck, S. L. Effects of aspirin on colorectal cancer related to lynch syndrome. J. Adv. Pract. Oncol. 3, 395–398 (2012).
pubmed: 25031971
pmcid: 4093361
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
pubmed: 4481136
pmcid: 4481136
Franz, D. N. et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One 11, e0158476 (2016).
pubmed: 27351628
pmcid: 4924870
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03207347 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01981525 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03448718 . (2020).
Smith, A. J., Oertle, J. & Prato, D. Environmental carcinogens and the kinds of cancers they cause. Open J. Oncol. (2014).
Yoshida, K. et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature 578, 266–272 (2020).
pubmed: 31996850
pmcid: 7021511
Merlino, G. & Noonan, F. P. Modeling gene-environment interactions in malignant melanoma. Trends Mol. Med. 9, 102–108 (2003).
pubmed: 12657431
Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453 (2016).
pubmed: 27433846
pmcid: 4986616
Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in Malignant Mesothelioma. J. Clin. Oncol. 36, 2863–2871 (2018).
pubmed: 30113886
pmcid: 6804864
Hassan, R. et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc. Natl Acad. Sci. USA 116, 9008–9013 (2019).
pubmed: 30975761
Guerin, A. et al. IRF4 haploinsufficiency in a family with Whipple’s disease. eLife 7, e32340 (2018).
pubmed: 29537367
pmcid: 5915175
Boisson-Dupuis, S. et al. Tuberculosis and impaired IL-23-dependent IFN-gamma immunity in humans homozygous for a common TYK2 missense variant. Sci. Immunol. 3, eaau8714 (2018).
pubmed: 30578352
pmcid: 6341984
Cirulli, E. T. et al. Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nat. Commun. 11, 542 (2020).
pubmed: 31992710
pmcid: 6987107
Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179–204 (2010).
pubmed: 20965415
pmcid: 2988877
Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085–2088 (1998).
pubmed: 9851930
Brunkow, M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68–73 (2001).
pubmed: 11138001
Hsu, P. P. & Sabatini, D. M. Cancer cell metabolism: Warburg and beyond. Cell 134, 703–707 (2008).
pubmed: 18775299
Warburg, O. On respiratory impairment in cancer cells. Science 124, 269–270 (1956).
pubmed: 13351639
Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G. & Galluzzi, L. Mitochondrial metabolism and cancer. Cell Res. 28, 265–280 (2018).
pubmed: 29219147
Peel, J. B. et al. A prospective study of cardiorespiratory fitness and breast cancer mortality. Med. Sci. Sports Exerc. 41, 742–748 (2009).
pubmed: 19276861
pmcid: 3774121
LeBleu, V. S. et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 1001–1015 (2014).
Tan, A. S. et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 21, 81–94 (2015).
Sullivan, L. B., Gui, D. Y. & Vander Heiden, M. G. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat. Rev. Cancer 16, 680–693 (2016).
pubmed: 27658530
Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857–866 (2005).
pubmed: 16327764
Sciacovelli, M. & Frezza, C. Oncometabolites: unconventional triggers of oncogenic signalling cascades. Free Radic. Biol. Med. 100, 175–181 (2016).
pubmed: 27117029
pmcid: 5145802
Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
pubmed: 19935646
pmcid: 2818760
Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656–659 (2012).
pubmed: 4005896
pmcid: 4005896
Inoue, S. et al. Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell 30, 337–348 (2016).
pubmed: 27424808
pmcid: 5022794
Nowicki, S. & Gottlieb, E. Oncometabolites: tailoring our genes. FEBS J. 282, 2796–2805 (2015).
pubmed: 25864878
pmcid: 4676302
Sabharwal, S. S. & Schumacker, P. T. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat. Rev. Cancer 14, 709–721 (2014).
pubmed: 25342630
pmcid: 4657553
Sumpter, R. Jr. et al. Fanconi anemia proteins function in mitophagy and immunity. Cell 165, 867–881 (2016).
pubmed: 27133164
pmcid: 4881391
Weinberg, C. R., Brown, K. G. & Hoel, D. G. Altitude, radiation, and mortality from cancer and heart disease. Radiat. Res. 112, 381–390 (1987).
pubmed: 3685264
Sung, H. J. et al. Ambient oxygen promotes tumorigenesis. PLoS One 6, e19785 (2011).
pubmed: 21589870
pmcid: 3093396
Simeonov, K. P. & Himmelstein, D. S. Lung cancer incidence decreases with elevation: evidence for oxygen as an inhaled carcinogen. PeerJ 3, e705 (2014).
Sung, H. J. et al. Mitochondrial respiration protects against oxygen-associated DNA damage. Nat. Commun. 1, 1–8 (2010).
Harris, I. S. et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27, 211–222 (2015).
pubmed: 25620030
Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug. Discov. 12, 931–947 (2013).
pubmed: 24287781